Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Rare Diseases

Lung Neoplasms

Small Cell Lung Carcinoma

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Small Cell Lung Cancer

Antineoplastic Agents

All Drugs and Chemicals

Topotecan

Somatostatin

Pasireotide

Topoisomerase I Inhibitors

Enzyme Inhibitors

Hormones

Hormone Antagonists

Topotecan 1.5mg/m2 dailyx5 days and Pasireotide 60 mg IM every 28 days

Topotecan and Pasireotide

Niramol Savaraj, M.D.

Vy Dinh, M.D.

The majority of small cell lung cancer(SCLC)(50-100%) express somatostatin receptors(type 1-5) with some small cell lung cancer express more than one subtypes. Stimulation of these SSTR's lead to inhibition of angiogenesis and cell growth. SOM230 also lower levels of IGF which is known to contribute to SCLC proliferation. Topotecan is approved for second line therapy in relapsed small cell lung cancer. We hypothesized that combination of both agents should yield greater antitumor activity.

The primary objectives of this study is to assess the progression-free survival (PFS) with the combination of SOM230 and topotecan in patients with SCLC who relapsed or progressed after front-line chemotherapy with cisplatin and etoposide. The secondary objective is to evaluate the efficacy and safety of SOM230 in combination with topotecan in this population. The primary end point is progression free survival. The secondary objective is response rate duration of response , overall survival , safety and tolerability. Patient who is eligible for the study will received topotecan 1.5mg/m2 on day 1-5 and SOM230 60mg on day 1 every 28 days until tumor progression or toxicity limit further treatment. Contrast-enhanced CT scans will be performed at baseline and every 2 months (or sooner if clinically indicated) to assess the response, duration of response, and time to tumor progression Patients will be allowed to remain on therapy if treatment is tolerated and if there is no evidence of progression for a maximum of 1 year or unacceptable toxicity occurs.

Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer

A Phase II Trial of SOM230(PasireotideLAR) and Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer

Primary outcome Progression free survival (PFS).

Secondary outcome Response rate (RR), duration of response, overall survival (OS), safety and tolerability

Novartis Pharmaceuticals

South Florida Veterans Affairs Foundation for Research and Education

Niramol Savaraj, M.D. Lucy Chua M.D. Vy Dinh M.D. Medhi Wangpaichits PhD

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer	NCT01417806	Small Cell Lung...	Topotecan and P...	18 Years -	South Florida Veterans Affairs Foundation for Research and Education
Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer	NCT01417806	Small Cell Lung...	Topotecan and P...	18 Years -	South Florida Veterans Affairs Foundation for Research and Education

Spots Global Cancer Trial Database for topotecan and pasireotide